Computed tomographic colonography with a reduced dose of laxative using a novel barium sulfate contrast agent in Japan

Purpose To test the tagging efficacy, patient acceptability, and accuracy of computed tomographic colonography (CTC) with a reduced dose of laxative using a novel barium sulfate (BaSO 4 ) contrast agent. Materials and methods CTC followed by optical colonoscopy (OC) was performed on 73 patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Japanese journal of radiology 2019-03, Vol.37 (3), p.245-254
Hauptverfasser: Mitsuzaki, Katsuhiko, Iinuma, Gen, Morimoto, Tsuyoshi, Miyake, Mototaka, Tomimatsu, Hideto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose To test the tagging efficacy, patient acceptability, and accuracy of computed tomographic colonography (CTC) with a reduced dose of laxative using a novel barium sulfate (BaSO 4 ) contrast agent. Materials and methods CTC followed by optical colonoscopy (OC) was performed on 73 patients with positive results in fecal occult blood tests. They were administrated a BaSO 4 suspension and a magnesium citrate solution for bowel preparation. Patients completed a questionnaire about the acceptability of bowel preparation. Tagging efficacy was estimated using a novel categorization system, which classified all segments into 8 categories. The accuracy of detecting protruded lesions ≥ 6 mm was calculated from the comparison of CTC and OC results, using the latter as a reference standard. Results Tagging efficacy was good in 77.3% of colonic segments where residue was observed. The acceptability of bowel preparation for CTC was significantly higher than that for OC. The sensitivity, specificity, and positive and negative predictive values were 0.778, 0.945, 0.824, and 0.929, respectively. All lesions ≥ 7 mm were successfully detected by CTC. Conclusion CTC with a reduced dose of laxative using a novel BaSO 4 contrast agent has a favorable tagging efficacy, patient acceptability, and accuracy.
ISSN:1867-1071
1867-108X
DOI:10.1007/s11604-018-0800-x